UBS Group’s Krystal Biotech KRYS Stock Holding History

UBS Group’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$892K	Buy	+2,400	New	+$717K	﹤0.01%	5827

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group's KRYS Position: Q2 2026 in Review

UBS Group increased its Krystal Biotech (KRYS) stake by 3.3% in Q2 2026, buying an estimated $1.43M and bringing the position to 148,316 shares worth $55.1M. The position accounts for 0.01% of the portfolio, ranked #1646.

UBS Group first reported a position in KRYS in Q3 2017 and has held it in 30 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

UBS Group held 148,316 shares of Krystal Biotech worth $55.1M as of Q2 2026.
UBS Group bought 4,791 Krystal Biotech shares in Q2 2026, an estimated $1.43M.
Krystal Biotech made up 0.01% of UBS Group's portfolio in Q2 2026, its #1646 holding.
UBS Group first reported a position in Krystal Biotech in Q3 2017 and has held it in 30 quarters since.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.